BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26323606)

  • 21. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
    Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
    Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
    Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
    Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
    Freyschlag CF; Tuettenberg J; Lohr F; Thomé C; Schmieder K; Seiz M
    Anticancer Res; 2011 Mar; 31(3):1023-5. PubMed ID: 21498732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
    Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
    J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
    Chamberlain MC
    J Neurooncol; 2015 Apr; 122(2):329-38. PubMed ID: 25563816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
    Kocher M; Frommolt P; Borberg SK; Rühl U; Steingräber M; Niewald M; Staar S; Stuschke M; Becker G; Fischedick AR; Herfarth K; Grauthoff H; Müller RP
    Strahlenther Onkol; 2008 Nov; 184(11):572-9. PubMed ID: 19016015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
    Levin N; Lavon I; Zelikovitsh B; Fuchs D; Bokstein F; Fellig Y; Siegal T
    Cancer; 2006 Apr; 106(8):1759-65. PubMed ID: 16541434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
    Reyes-Botero G; Laigle-Donadey F; Mokhtari K; Martin-Duverneuil N; Delattre JY
    J Neurooncol; 2014 Dec; 120(3):581-6. PubMed ID: 25139026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
    Yung WK; Prados MD; Yaya-Tur R; Rosenfeld SS; Brada M; Friedman HS; Albright R; Olson J; Chang SM; O'Neill AM; Friedman AH; Bruner J; Yue N; Dugan M; Zaknoen S; Levin VA
    J Clin Oncol; 1999 Sep; 17(9):2762-71. PubMed ID: 10561351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of salvage treatment for recurrent glioblastoma.
    Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
    J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rechallenge temozolomide in glioma: A case series from India.
    Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
    Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
    Huang F; Kavan P; Guiot MC; Markovic Y; Roberge D
    Can J Neurol Sci; 2008 May; 35(2):192-7. PubMed ID: 18574933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
    Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.